Industry perspective on pediatric HIV vaccine development. Marguerite Koutsoukos Director, Vaccine Development Leader, GSK
|
|
- Jane Daniels
- 5 years ago
- Views:
Transcription
1 Industry perspective on pediatric HIV vaccine development Marguerite Koutsoukos Director, Vaccine Development Leader, GSK 2 nd Workshop on Prevention Trials in Infants Born to HIV-Positive Mothers Maputo, Feb 7 th, 2017
2 Some insights from the pediatric Malaria vaccine development 2
3 Despite major efforts in malaria control over past decade, the malaria disease burden remains unacceptably high One child dies from malaria every 2 minutes WORLDWIDE 214 million malaria cases in ,000 deaths in 2014 Mostly in children <5y (70%) WHO African Region 188 million cases - 88% of total burden - Mainly P. falciparum 395,000 deaths - 90% of total burden - 74% in children <5y Significant cost and annual loss of economic growth Prevalence of P. falciparum in infants between 2-10 years of age in 2014 ( WHO World Malaria Report 2015 (data from 2014) 3
4 The age of peak incidence of malaria depends on the transmission intensity Maternal antibodies provide partial protection during the first 3 months of life. Natural immunity develops over time against clinical manifestations of malaria (blood stage) Development of natural immunity depends on frequency and duration of parasite exposure (intensity of malaria transmission) The age category with the highest malaria incidence depends on the speed of acquisition of natural immunity. Age distribution of hospitalised malaria in areas with different malaria transmission HIGH Peak Incidence in less than 1y Tanzania, Namawala/Michenga (1991-2) PfPR 2-10 = 87% MODERATE Peak Incidence between 1 and 3y The Gambia, Sukuta (1992-5) PfPR 2-10 = 42% 60 LOW Similar incidence throughout childhood Yemen, Hodeidahk(2002-4) PfPR 2-10 = 2% % Age (years) Snow RW et al. J Infect Dis 1998; 177: Mutabingwa TK et al. PLoS Med 2005; 2:e407 Okiro EA et al. Malar J 2009; 8:4 - Guinovart C et al. Malar J 2008; 7:36. 4
5 The RTS,S malaria vaccine development programme: A 30-year effort from GSK and successful partnerships 1984 GSK/WRAIR initiate collaboration 1995 First clinical tests begin in adults in US 1998 First trials in Africa begin in the Gambia (4) 2004 Key Proof-of- Concept study in children in Mozambique (1,8) 2009 Phase III efficacy study start 2011 First Phase III efficacy results in 5-17 months old over 12 months of follow-up (11) 2013 Third Phase III efficacy results over 18 months of followup and per study site (13) 2015 Final Phase III efficacy results including 3-4 years of follow-up and effect of 4 th dose of RTS,S (14) 1987 RTS,S first created by combining the malaria CS protein and hepatitis B surface antigen 1997 Key proof-ofconcept study shows 6 out of 7 volunteers in challenge trial are fully protected (3) 2001 GSK/MVI partnership initiated 2007 Phase II results in African children (5) and infants (2,10) 2011 Key Phase II efficacy results in African children (6) and infants (7,9) 2012 Second Phase III efficacy results in 6-12 weeks old over 12 months of follow-up (12) 2014 File submitted to the European Medicines Agency (EMA) 2015 EMA Positive Scientific Opinion granted (15) WHO recommends pilot introduction (16) (1) Alonso P et al. Lancet 2004; (2) Aponte J et al. Lancet 2007; (3) Stoute J et al. NEJM 1997; (4) Doherty J et al. AJTMH 1999; (5) Bejon P et al. NEJM 2008; (6) Olotu A et al. Lancet ID 2011; (7) Asante KP et al. Lancet ID 2011; (8) Sacarlal J et al. JID 2009; (9) Agnandji ST et al. JID 2010; (10) Abdulla S et al. NEJM 2008; (11) RTS,S Clinical Trials Partnership. NEJM 2011; (12) RTS,S Clinical Trials Partnership. NEJM 2012; (13) RTS,S Clinical Trials Partnership. PLoS Med 2014; (14) RTS,S Clinical Trials Partnership. Lancet 2015; (15) (16) 5
6 Mosquirix : the start of the next journey From vaccine to vaccination EMA Positive Scientific Opinion (July 2015) IM administration 3 doses at 1-month interval 4th dose months later WHO policy recommendation (January 2016) Pre-qualification procedure Marketing authorization applications NRA licensure in African countries Procurement by UN agencies Start Phase IV studies and pilots: benefit-risk in real-life settings (2018) 6
7 Some similarities but also major differences between HIV and Malaria vaccine development Malaria HIV Prevention of disease Availability of human challenge model Relatively easy to show efficacy in Phase II studies Major burden of disease in 6m- 1y old babies Efficacy level ~50 % Recommended malaria preventive interventions fully implemented in clinical trials Schedule aligned to EPI to improve coverage Prevention of infection Predictability of Non Human Primate challenge model still questionable Demonstration of efficacy requires large studies Major burden of infection in > aged 15+ Expected efficacy level ~ 50 % Use of recommended preventions in clinical trials Which vaccination platform depending on age and schedule 7
8 GSK prophylactic HIV vaccine development 8
9 HIV still a major challenge In 2015, There were 36.7 million [34.0 million 39.8 million] people living with HIV Africa Adult HIV prevalence Worldwide, 2.1 million [1.8 million 2.4 million] people became newly infected with HIV Eastern and southern Africa accounts for 46% of the global total of new HIV infections Around 46% [43 50%] of all people living with HIV had access to treatment 1.1 million [ million] people died from AIDS-related illnesses AFRIDEVINFO 2016 UNAIDS FACT SHEET NOVEMBER
10 GSK HIV vaccine program Some historical perspective Involvement in HIV vaccine development since the early days Both prophylactic and therapeutic approaches Several candidates in the clinics Requirement for specific of immune response and development of potential candidates = moving target PRO HIV-005 TH HIV-008 TH HIV-010 TH HIV-011 Challenging program Adjuvanted Proteins F4co/AS (p24, RT, Nef,p17) Public & private partnership CD4 (bn)ab gp120/neftat/as CD8 MV1-F4 Vectors HuAd35-GRIN HIV-001 HVTN-041 PRO-HIV-002 TH HIV-007 PRO HIV-011 PRO HIV
11 In the field, all vaccine efficacy trials have failed, except one Trial Vaccine Components Efficacy VAX 004 gp120 (B/B) / Alum No VAX 003 gp120 (B/E) / Alum No STEP RV144 HVTN 505 Ad5 (gag, pol, nef (B) ALVAC (gag, pol, env) (B/E) + gp120 (B/E) / Alum DNA (gag, pol, nef) (B) DNA (env)(a/b/c) + Ad5 (gag, pol) (B) Ad5 (env) (A/B/C) No Yes (31 %) No Adapted from Vaccine 2013; 31(35):
12 RV144: first efficacy results bring some hope 16,402 men and women between the ages of 18 and 30 years in Thailand VE 31.2% [1.1 to 52.1; p=0.04] at 3,5 y Post-hoc VE 60.5% at 1 year but rapidly thereafter High gp70-v1v2 binding IgG and low IgA antibodies binding to Env seem to correlate with risk reduction NEJM 2009;361(23): Lancet 2012;12(7): NEJM 2012;366(14): Lancet Infect Dis 2012;12:
13 Pox-Protein Public & Private Partnership P5 Established in 2010 to build on the success of RV144 results To advance and ultimately license HIV pox-protein vaccine candidates that have the potential to achieve a broad public health impact 14
14 P5 Strategy: focus on Southern Africa Construct Bivalent Subtype C gp120 / MF59 Construct ALVAC-HIV-C (vcp2438) Add Booster at 12 months Optimize regimen for regional relevance, increased potency, and durability 15
15 HVTN 702 efficacy launched 16
16 What about pediatric HIV vaccine development 17
17 Global / regional new HIV infection data New infections Region Total Aged 15+ Aged 0 14 Global 2,1 million (1,8 million 2,4 million) 1,9 million (1,7 million 2,2 million) ( ) Eastern and Southern Africa ( ,1 million ( ,1 million) ( ) Western and Central Africa ( ) ( ) ( ) Ø 6% of new infections in Eastern and Southern Africa are found in aged 0-14 Ø Situation in 10 years from now Nov
18 Regional antiretroviral therapy 2015 % of adults (aged 15+) living with HIV accessing antiretroviral therapy Global 46 % (43 50%) % of children (aged 0-14) living with HIV accessing antiretroviral therapy 49 % (42 55 %) % of pregnant women accessing antiretroviral medicines to prevent mother-tochild transmission of HIV 77 % (69 86 %) Eastern and Southern Africa 53 % (50 57 %) 63 % (56 71 %) 90 % (82 95 %) Western and Central Africa 29 % (24 35 %) 20 % (16 25 %) 48 % (40 58 %) Ø % of children aged 0-14 accessing therapy in Eastern and Southern Africa can still to be improved Nov
19 Mother-to-child HIV transmission Mother-to-child transmission (MTCT) accounts for over 90% of new HIV infections among children MTCT from HIV-infected mother to her child through: pregnancy, delivery, breastfeeding Probability of HIV transmission Without treatment With ART treatment % < 5% Prevention of Mother-to-child transmission (PMTCT) includes: Prevention of HIV transmission Prevention of infection in women of childbearing potential Prevention of unintended pregnancies Treatment of HIV infected mothers, their children, their family 20
20 Global plan for PMTCT: results depending on countries 21
21 Barriers to PMTCT Knowledge about HIV, MTCT and PMTCT Knowledge of HIV status Confusion over exclusive breastfeeding HIV stigma, discrimination and PMTCT, stigma in healthcare settings Country and clinic resources Early infant diagnosis; immediacy of treatment initiation Cultural beliefs and gender dynamics; male involvement Role of vaccination 22
22 GSK Target Product Profile adapted to MTCT: questions HIV Prophylactic Primary target indication Primary target population Efficacy endpoint Duration of protection Dosage, admin & schedule Interaction / Co-Ads Safety Target Product Profile Prevention of HIV infection (all clades) ENDEMIC REGION Minimum Product Profile Prevention of HIV infection (clade C or A) Pregnant women (seronegative / seropositive) New-borns from infected mothers Infants from infected mothers Toddlers Not inferior to standard of care 1 year IM (1-3 doses) Which schedule No interference with other vaccination (pregnant women ie. Boostrix, Flu; infants ie. BCG, EPI) Clinically acceptable safety profile + Safe in HIV seropositive Shelf-life/storage Thermostable, 3 years Storage at 2 C to 8 C; 3 years Presentation AD syringes + safety boxes Vials + safety boxes 23
23 Key points to consider Maturity of immune system in neonates and infants Interference with maternal antibodies Impact of different mode of HIV transmission (blood milk versus sexual): will a vaccine that protects from HIV infection though sexual contact also protect from mother-to-child transmission Difficulty to identify correlate of protection Different correlate of protection Different epitope-specificity Need for safety and efficacy data in adults population before Need for age de-escalation safety & immunogenicity studies Which efficacy trial 24
24 Key points to consider Efficacy trial design Groups /objectives Is it ethical to randomize to placebo recipients Is it ethical to test a vaccine on its own Non-inferiority as compared to ART treatment Add-on to ART-treatment à superiority to ART treatment à Impact on sample size Treatment 1 Placebo 2 Vaccine 3 ART + Control 4 ART + Vaccine à Feasibility to enroll enough subjects Screening Infection Maternal antibodies 25
25 Key points to consider Maturity of immune system in neonates and infants Interference with maternal antibodies Impact of different mode of HIV transmission (blood milk versus sexual): will a vaccine that protects from HIV infection though sexual contact also protect from mother-to-child transmission Difficulty to identify correlate of protection Different correlate of protection Different epitope-specificity Need for safety and efficacy data in adults population before Need for age de-escalation safety & immunogenicity studies Which efficacy trial Vaccine implementation 26
26 Key points to consider Vaccine implementation in low resources settings Vaccines considered as most inexpensive means of improving health and lowering mortality and morbidity caused by infectious diseases However wide implementation remains a challenge (vaccines licensed since 10 years, proven to be safe and effective, at low price and still not part of national immunization programs) Many obstacles and challenges remain Medical & scientific: lack of awareness, limited data on disease burden, malnutrition, multiple infections, altered immune status, appearance of emerging and new pathogens; new improved vaccine: technologically sophisticated, safety and acceptability Structural & demographic: rapid urbanization, overcrowding cities, poor sanitation, movement of migrants, missed immunization schedules, poor infrastructure, logistic problems, expanding populations Economic and political: limited resources, affordability of vaccines and maintenance of vaccine infrastructure, competing priorities, resistance to innovation Societal & cultural: poverty, illiteracy, religious taboos, superstition, irrational fears 27
27 Key points to consider Maturity of immune system in neonates and infants Interference with maternal antibodies Impact of different mode of HIV transmission (blood milk versus sexual): will a vaccine that protects from HIV infection though sexual contact also protect from mother-to-child transmission Difficulty to identify correlate of protection Different correlate of protection Different epitope-specificity Need for safety and efficacy data in adults population before Need for age de-escalation safety & immunogenicity studies Which efficacy trial Vaccine implementation Public health impact 28
28 Importance to complement Vaccine Efficacy estimates with estimates of potential Public Health Impact Vaccine efficacy needs to be translated into public health impact in order to understand the true absolute value of vaccination: Example: The effect of Human Rotavirus Vaccine on severe rotavirus gastroenteritis in the first year of life in Malawi and South Africa Malawi South Africa - Vaccine Efficacy 49 % 77 % - Baseline incidence (episodes/1,000 infants/year) - Number of severe rotavirus gastroenteritis cases averted (per 1,000 PYAR) Madhi S. et al. NEJM 2010;362:
29 Key points to consider Maturity of immune system in neonates and infants Impact of different mode of HIV transmission (blood milk versus sexual): will a vaccine that protects from HIV infection though sexual contact also protect from mother-to-child transmission Difficulty to identify correlate of protection Different correlate of protection Different epitope-specificity Need for safety and efficacy data in adults population before Need for age de-escalation safety & immunogenicity studies Which efficacy trial Vaccine implementation Public health impact Access and costs 30
30 Key points to consider Access and costs One in five children in Africa still does not receive basic life-saving vaccines GAVI support to developing countries focused on introduction and increase of access to vaccines to protect every child with a full package of WHO-recommended life-saving vaccines GAVI support, eligibility and transition policy: Eligibility support determined by the country s Gross National Income (GNI) per capita according to World Bank data (< threshold) Once threshold achieved, countries enter an accelerated transition process and start phasing out of GAVI support. During this period, GAVI will intensify its efforts to help transitioning countries be in a good position to financially sustain their immunisation programmes and new vaccines 31
31 Next steps Further define burden of disease and need for vaccination in different populations, age groups, countries à vaccination of adolescents/adults of childbearing potential, neonates, infants, maternal immunization Better understand immune responses required depending on the transmission route Better understand the immune response in neonates and infants Further explore correlate of protection Try and anticipate armamentarium availability in 10 years from now Maximize preventative antiretroviral treatment; improve access to treatment Consultations Regulatory authorities, WHO, GAVI 32
32 Conclusions The level of infection through mother-to-child transmission much lower than through sexual transmission Vaccine development path not clear, since many questions still to be answered Epidemiological situation and preventative armamentarium will further evolve until a vaccine could be ready for implementation Focus on vaccine development for adolescents / adult women with childbearing potential Should we consider maternal immunization Need to reflect on all these questions before launching a pediatric vaccination program 33
33 Acknowlegements HIV Bill & Melinda Gates Foundation Nina Russell, Pervin Anklesaria DAIDS, NIH HVTN IAVI Mary Marovitch, Mike Pensiero Larry Corey, Jim Kublin, Julie Mc Elrath, Glenda Gray Angela Lombardo, Fran Priddy, Jo Cox, Eddy Sayeed, Jim Ackland Duke University Barton Haynes, Georgia Tomaras Center for Vaccinology, Ghent University and Hospital Geert Leroux-Roels, Eva. Van Braeckel, Frédéric Clément Institut Pasteur FrédéricTangy Ragon Institute of Massachussetts General Hospital Bruce Walker, Mathias Lichterfeld, Marcus Altfeld Study staffs, study volunteers and families All investigators involved in the therapeutic program GSK & Novartis Vaccine Development Teams Malaria Study volunteers and families Study staff PATH Malaria Vaccine Initiative Malaria Clinical Trials Alliance Bill & Melinda Gates Foundation World Health Organization GSK Malaria Vaccine Development Teams 34
34 Thank you
HIV Vaccine Clinical Trials at CIDRZ
HIV Vaccine Clinical Trials at CIDRZ Developing a Safe and Effective Vaccine for Prevention of HIV Infections Globally Christine Namakobo Senior Research Nurse Matero Clinical Research Site State of Global
More informationHVTN P5 Vaccine Trials
HVTN P5 Vaccine Trials Erica Andersen-Nissen, PhD Director, Cape Town HVTN Immunology Laboratory Considerations for a Pan-African HIV Vaccine Development Agenda Kigali, Rwanda 16-17 March 2015 HVTN Mission
More informationOverview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018
Overview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018 1 Objectives Brief review Background EMA positive opinion and WHO recommendations Funding Description
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationPlanned Vaccine Trials to Follow-up on RV 144. Merlin Robb, MD Deputy Director for Clinical Research MHRP
Planned Vaccine Trials to Follow-up on RV 144 Merlin Robb, MD Deputy Director for Clinical Research MHRP Planned studies are mutually reinforcing and will amplify public health impact and regional relevance
More informationMaternal Immunization: Unique considerations of public health value of vaccines given to pregnant women
Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine
More informationEnhancing Immunogenicity of Recombinant Vaccines: Chemical Conjugation
Enhancing Immunogenicity of Recombinant Vaccines: Chemical Conjugation Malaria vaccine development and a role for conjugates Ashley J Birkett, PhD Director, Research & Development New Cells, New Vaccines
More informationBRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC
BRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC Introduction Date: 12 August 2012. Author: WHO Secretariat with input from JTEG Chair The most advanced vaccine candidate against
More informationThe Kitchen Sink. Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona
The Kitchen Sink Glenda Gray AIDS vaccine at the cross roads: how to adapt to a new preven9on age? Monday 7 th October, 2013, Barcelona The only important slide of my presentation. All efficacy trial in
More informationStatus of RTS,S/AS01 malaria vaccine candidate
Status of RTS,S/AS01 malaria vaccine candidate Multi-center RTS,S malaria vaccine efficacy trial Phase 3, randomized, controlled, double-blind trial conducted in 11 centers in 7 African countries 15,460
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationDeveloping a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
More informationRSV vaccine research and development: WHO technical roadmap
RSV vaccine research and development: WHO technical roadmap Johan Vekemans (MD, PhD) WHO Initiative for Vaccine Research Washington, 18 th December 2017 What is WHO s Initiative for Vaccine Research (IVR)
More informationElimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014
Elimination of mother to child transmission of HIV: is the end really in sight? Lisa L. Abuogi, MD University of Colorado, Denver Dec 3, 2014 Outline Background History of prevention of mother to child
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationCase study of formulating two Subtype C gp120 proteins
Case study of formulating two Subtype C gp120 proteins Antu Dey, DPhil. Senior Director, IAVI (formerly at GSK Vaccines) Associate Project Leader HIV Research Head Formulation Sciences & Process Development
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationAnalysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries
Briefing Document: National decision-making framework for malaria vaccines Analysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries This is one of seven briefing
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationGAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment
GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationNew vaccine technologies: Promising advances may save more lives
New vaccine technologies: Promising advances may save more lives Vaccine Technology III June 10, 2010 PATH s vision A world where innovation ensures that health is within reach for everyone. 2 PATH s mission
More informationMaternal Influenza Immunization at WHO
Maternal Influenza Immunization at WHO Dr. Justin R. Ortiz Medical Officer Initiative for Vaccine Research GAP Partners Meeting Dubai, UAE 26 March 2014 WHO Position Paper Mother s Gift Trial GAVI Review
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationElimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:
Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,
More informationHIV Vaccine. 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง
HIV Vaccine 15 September 2016 นพ.นคร เปรมศร ผ อ านวยการส าน กงาน โครงการศ กษาว คซ นเอดส ทดลอง GLOBAL STATISTICS 2015 17 million people were accessing antiretroviral therapy 36.7 million people globally
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More information4/14/2016. HIV Vaccines and Immunoprotection: Where Are We? Learning Objectives. After attending this presentation, participants will be able to:
HIV Vaccines and Immunoprotection: Where Are We? Mark J. Mulligan, MD, FIDSA Distinguished Professor of Medicine Emory University School of Medicine Atlanta, Georgia FINAL: 04/01/16 Atlanta, Georgia: Friday,
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationThe outlook for hundreds of thousands adolescents is bleak.
Adolescents & AIDS Dr. Chewe Luo Chief HIV/AIDS, UNICEF Associate Director, Programmes Division 28/11/17 Professor Father Micheal Kelly Annual Lecture on HIV/AIDS Dublin, Ireland The outlook for hundreds
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationtransmission (MTCT) of
Training Course in Sexual and Reproductive Health Research 2013 Module: Principles and Practice of Sexually Transmitted Infections Prevention and Care Dual elimination of mother-to-child transmission (MTCT)
More informationThe elimination equation: understanding the path to an AIDS-free generation
The elimination equation: understanding the path to an AIDS-free generation James McIntyre Anova Health Institute & School of Public Health & Family Medicine, University of Cape Town Elimination of perinatal
More informationMaternal, Child and Reproductive Health Initiative
Maternal, Child and Reproductive Health Initiative Maternal, Child and Reproductive Health Initiative The Maternal, Child and Reproductive Health (MCRH) Initiative works in developing countries to improve
More information2018 INFUSE CALL FOR INNOVATION
2018 INFUSE CALL FOR INNOVATION Leveraging digital technologies for registration, identification, digital record-keeping and follow-up to ensure healthier futures Imagine a future in which all children
More informationInformation for Access
Information for Access WHO Efforts to Enhance Access to Vaccine Supply UNICEF Vaccine Industry Consultation Copenhagen, October 2017 Tania Cernuschi, Vaccine Supply Supply, Technologies, and Financing
More informationPrevention of HIV in infants and young children
WHO/HIV/2002.08 Original: English Distr.: General Prevention of HIV in infants and young children A major public health problem HIV among children is a growing problem, particularly in the countries hardest
More informationWHO/HIV_AIDS/BN/ Original: English Distr.: General
WHO/HIV_AIDS/BN/2001.1 Original: English Distr.: General It is estimated that 4.3 million children have died of AIDS before their fifteenth birthday, nearly half a million in 2000. Another 1.4 million
More informationChildren and AIDS Fourth Stocktaking Report 2009
Children and AIDS Fourth Stocktaking Report 2009 The The Fourth Fourth Stocktaking Stocktaking Report, Report, produced produced by by UNICEF, UNICEF, in in partnership partnership with with UNAIDS, UNAIDS,
More informationAdvancing HIV Vaccines into Efficacy studies. Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland
Advancing HIV Vaccines into Efficacy studies Glenda Gray WHO PD VAC 7-9 September 2015 Geneva, Switzerland What we need to end AIDS: controlling viremia New classes of Drugs Point of care viral load &
More informationWPR/RC68/7 page 7 ANNEX
page 7 ANNEX DRAFT Regional Framework for the Triple Elimination of Mother-to-child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018 2030 page 8 page 9 Table of Contents Abbreviations....
More informationEconomic and Social Council
United Nations E/CN.6/2010/L.6 Economic and Social Council Distr.: Limited 9 March 2010 Original: English ADOPTED 12 March 2010 ADVANCE UNEDITED VERSION Commission on the Status of Women Fifty-fourth session
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationDevelopment of a Malaria Vaccine for Sub-Saharan African Children December 3, 2009 Lode Schuerman
Development of a Malaria Vaccine for Sub-Saharan African Children December 3, 2009 Lode Schuerman Copyright John-Michael Maas, Darby Communications Agenda Malaria Disease burden Prevention and vaccine
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationTOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV
TOWARDS ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV Gladwel Muthoni KPA Conference 24 th April, 2018 OUTLINE Burden of HIV in PMTCT Mechanism and timing of Mother to Child Transmission (MTCT) Four
More informationVACCINE MARKETS OVERVIEW SESSION
VACCINE MARKETS OVERVIEW SESSION Robyn Iqbal Program Officer, Vaccine Delivery Market Dynamics UNICEF SD Manufacturers Meeting Copenhagen October 8, 2014 DRAFT Bill & Melinda Gates Foundation DISCUSSION
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationPerspectives on HIV/AIDS and Breastfeeding. Cathy Liles MPH, IBCLC La Leche League International Chicago, Illinois July 10, 2001
Perspectives on HIV/AIDS and Breastfeeding Cathy Liles MPH, IBCLC La Leche League International Chicago, Illinois July 10, 2001 Introduction: HIV/AIDS First recognized in 1981 Virus identified in 1983
More informationCan we improve the performance of live oral rotavirus vaccines?
Can we improve the performance of live oral rotavirus vaccines? Duncan Steele 9 th International Rotavirus Symposium 2 & 3 August 2010, Johannesburg, South Africa Vaccine efficacy against severe rotavirus
More informationResolution adopted by the General Assembly. [without reference to a Main Committee (A/62/L.39 and Add.1)]
United Nations General Assembly Distr.: General 7 March 2008 Sixty-second session Agenda item 47 Resolution adopted by the General Assembly [without reference to a Main Committee (A/62/L.39 and Add.1)]
More informationA Briefing Paper on Rotavirus
COMMON VIRUS AND SENSELESS KILLER: A Briefing Paper on Rotavirus DIARRHEA KILLS. MOTHERS IN THE WORLD S POOREST COUNTRIES KNOW THIS ALL TOO WELL. It s a fact few people in wealthier nations realize. Rotavirus
More informationMay HIV Vaccines: The Basics
May 2018 HIV Vaccines: The Basics Presentation Overview What is a vaccine? How would an HIV vaccine work? Where are we in the search? What is needed now? What is a Vaccine? A substance that teaches the
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationPerspectives on Ensuring Access to Vaccines in Lower Income Countries
Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS
More informationCatalyzing Progress Toward the Global Nutrition Targets: Three Potential Financing Packages
Catalyzing Progress Toward the Global Nutrition Targets: Three Potential Financing Packages By Meera Shekar, a Jakub Kakietek, a Julia Dayton Eberwein, a Mary D Alimonte, b Dylan Walters, a and Michelle
More informationEDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG. MBOUP Souleymane
EDCTP Third Forum PARTNERSHIP AND AFRICAN LEADERSHIP IN VACCINE RESEARCH AND HIV/AIDS DRUG MBOUP Souleymane HIV VACCINE IN AFRICA In 2005, 13 new trials of preventive AIDS vaccine candidates began in 9
More informationA Call to Action Children The missing face of AIDS
A Call to Action Children The missing face of AIDS Scaling up Paediatric HIV Care Treatment in resource limited settings Dr Chewe Luo MMed(Paed); MTropPaed; PhD UNICEF Health Section Programme Division
More informationConcept note. 1. Background and rationale
Concept note Inter-Country Workshops for Strengthening Regional and National Human Capacity to Accelerate Scaling up of National PMTCT and Paediatric Care, Support and Treatment Programmes TOWARDS UNIVERSAL
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationAccess to vaccination in GAVI countries and at global level
Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for
More information2013 progress report on the Global Plan
2013 progress report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive 210 000 the number of new HIV infections among children in (21
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationTHE GLOBAL STRATEGY FOR WOMEN S, CHILDREN S AND ADOLESCENTS HEALTH ( )
THE GLOBAL STRATEGY FOR WOMEN S, CHILDREN S AND ADOLESCENTS HEALTH (2016-2030) SURVIVE THRIVE TRANSFORM AT A GLANCE SURVIVE THRIVE TRANSFORM The Global Strategy for Women s, Children s and Adolescents
More informationDRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES
DRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES April 2005 Summary: Millions of children in developing countries are affected by the HIV/AIDS pandemic. Despite significant international
More informationRoadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap
Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationThresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016
Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology
More informationWhy should AIDS be part of the Africa Development Agenda?
Why should AIDS be part of the Africa Development Agenda? BACKGROUND The HIV burden in Africa remains unacceptably high: While there is 19% reduction in new infections in Sub-Saharan Africa, new infections
More informationGavi Alliance Strategy : Goal level indicators and disease dashboard
Gavi Alliance Strategy 2016-2020: Goal level indicators and disease dashboard BOARD MEETING Peter Hansen and Hope Johnson 10-11 June 2015, Geneva Reach every child www.gavi.org Strategic enablers Goal-level
More informationVaccines on the Global Scale
Vaccines on the Global Scale Learning from the past and aiming at the future Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health,
More informationPreconception care: Maximizing the gains for maternal and child health
POLICY BRIEF WHO/FWC/MCA/13.02 Preconception care: Maximizing the gains for maternal and child health A new WHO report shows that preconception care has a positive impact on maternal and child health outcomes
More informationFUNDERS UPDATE- BMGF. Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017
FUNDERS UPDATE- BMGF Third HIV Env Manufacturing Workshop Sponsored by DAIDS-NIAID-NIH and the HIV Global Vaccine Enterprise July 20-21, 2017 Susan Barnett Senior Program Officer, Product and Clinical
More informationDRAFT: Sexual and Reproductive Rights and Health the Post-2015 Development Agenda
DRAFT: Sexual and Reproductive Rights and Health the Post-2015 Development Agenda This draft working paper considers sexual and reproductive health and rights in the context of the post- 2015 framework.
More informationCountdown to 2015: tracking progress, fostering accountability
Countdown to 2015: tracking progress, fostering accountability Countdown to 2015 is a global movement to track, stimulate and support country progress towards achieving the health-related Millennium Development
More informationMALARIA VACCINE PILOTS
MALARIA VACCINE PILOTS BOARD MEETING Judith Kallenberg, Geneva Reach every child www.gavi.org Developments since 2013 (1/5) 2013 Malaria vaccine shortlisted in Vaccine Investment Strategy Board decision
More informationFAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030
Evidence informed, responsive and sustainable care FAST-TRACK: HIV Prevention, treatment and care to End the AIDS epidemic in Lesotho by 2030 Alti Zwandor UNAIDS Country Director Maseru, Lesotho 9 December
More informationAdvancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction
Advancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction Despite significant advances in child survival, deaths in the earliest
More informationIMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE. Bradford D. Gessner, MD Agence de Médecine Preventive
IMPORTANCE OF VACCINE PREVENTABLE DISEASE INCIDENCE Bradford D. Gessner, MD Agence de Médecine Preventive Vaccine Launches 2013 2 Disease burden has been consistently mentioned by policymakers in countries
More informationFinancial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment
Financial Resources for HIV: PEPFAR s Contributions to the Global Scale-up of Treatment Joint WHO & UNAIDS Consultation with Pharmaceuticals and Stakeholders November 05 2012 Lara Stabinski, MD, MPH Medical
More informationWHO Strategy and Goals for Viral Hepatitis Elimination
WHO Strategy and Goals for Viral Hepatitis Elimination No Disclosures Outline 1. Global strategy for elimination WHO targets and rationale 2. The global response so far Gaps in achieving the HBV and HCV
More informationStrategic Plan Annual Results Briefing
2014 Strategic Plan Annual Results Briefing HIV/AIDS Craig McClure Associate Director, HIV 15 June 2015 Danny Kaye CONTEXT AT OUTSET OF 2014 3.2m 240,000 23% vs. 37% 3.2 million children (0 14 years) living
More informationJTEG s Summary of RTS,S/ AS01 Clinical Trial Data
JTEG s Summary of RTS,S/ AS01 Clinical Trial Data Peter Smith On behalf of the Joint Technical Expert Group (JTEG) based on Cohen et al 2010 RTS,S/AS01 Malaria Vaccine l Based on large segment of P. falciparum
More informationMaternal, Adolescent, and Pediatric HIV/AIDS Therapeutics Clinical Trials Network:
Maternal, Adolescent, and Pediatric HIV/AIDS Therapeutics Clinical Trials Network: Pregnant Women in the NIAID HIV/AIDS Clinical Trials Network Recompetition Carl W. Dieffenbach, Ph.D. Director Division
More informationREPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES
Information Brief: REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES Family Care International (FCI) developed this information brief as part of the Mobilising Advocates
More informationProgress report on. Achievement of the Millennium Development Goals relating to maternal and child health
Regional Committee for the EM/RC52/INF.DOC.4 Eastern Mediterranean July 2005 Fifty-second Session Original: Arabic Agenda item 4 (d) Progress report on Achievement of the Millennium Development Goals relating
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More information